Administration of Antibiotics in Intensive Care Units
Conditions
Keywords
intensive care, antibiotic levels in blood samples
Brief summary
The primary objective of the DALI study is to compare antibiotic concentrations in patient blood samples with bacteriological objectives associated with maximum bactericidal activity. The antibiotics studied are certain lactams and glycopeptides.
Interventions
BIOLOGICALBlood sampling
Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient (or his/her trusted representative) must have given his/her informed and signed consent * Antibiotic treatment is administered with beta-lactams or glycopeptides administered continuously or intermittently (Can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin). * A vein or artery catheter is established to facilitate blood sampling (arterial catheter is preferred)
Exclusion criteria
* None of the above-mentioned antibiotics are administered * Impossible to establish venous or arterial catheter * Consent not given * Patient is pregnant, parturient or breastfeeding * The patient is under tutorship or curatorship * The patient is participating in another study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| [antibiotics] in blood versus bactericidal activity | 1/2 antibiotic dose interval (expected maximum of 4 days; days 1 to 4) | The primary endpoint for the DALI study is the comparison of antibiotic concentrations in patient blood samples with bacteriological objectives associated with maximum bactericidal activity. The antibiotics studied are certain lactams (endpoint pharmacokinetics 50 and 100% T\> MIC) and glycopeptides (100% T\> 4xCMI and report ASC0-24/CMI ≥ 350). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SOFA score | at time of blood sampling (day 1) | — |
| PIRO score | at time of blood sampling (day 1) | — |
| Apache II score | at time of blood sampling (day 1) | — |
| Indication for antibiotic treatment | at time of blood sampling (day 1) | — |
| did the patient have a surgical procedure in the last 24 hours? | at time of blood sampling (day 1) | yes/no |
| Diagnosis at admission | Admission to ICU (day 1) | — |
Countries
France
Outcome results
None listed